Depression in patients with mastocytosis: Prevalence, features and effects of masitinib therapy

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Moura, Daniela Silva ^a   Sultan, Serge ^a,b   Georgin Lavialle, Sophie ^a,c   Pillet, Nathalie ^d   Montestruc, François ^d   Gineste, Paul ^d   Barete, Stéphane ^e   Damaj, Gandhi ^f   Moussy, Alain ^d,g   Lortholary, Olivier ^a   Hermine, Olivier ^a,c,d,g  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITY OF MONTREAL   (Canada)

^c CNRS   (France)

^d AB Science SA   (France)

^e HÔPITAL TENON   (France)

^f UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^g Association Francaise pour les initiatives et la recherche sur les mastocytes et les mastocytoses   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MASITINIB; ANTINEOPLASTIC AGENT; THIAZOLE DERIVATIVE;

ADL DISABILITY; ADULT; ANXIETY; ARTICLE; CELL ACTIVATION; CLINICAL FEATURE; COHORT ANALYSIS; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GUILT; HAMILTON SCALE; HUMAN; HYPOCHONDRIASIS; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MAST CELL; MASTOCYTOSIS; OPEN STUDY; PREVALENCE; PRINCIPAL COMPONENT ANALYSIS; QUALITY OF LIFE; THINKING IMPAIRMENT; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION; AGED; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PSYCHOLOGICAL ASPECT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DEPRESSION; FEMALE; HUMANS; MALE; MASTOCYTOSIS; MIDDLE AGED; THIAZOLES; YOUNG ADULT;

EID: 80054848122     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026375     Document Type: Article

References (67)

1. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, et al. (2001) Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25: 603-625.
2. Lennert K, Parwaresch MR, (1979) Mast cells and mast cell neoplasia: a review. Histopathology 3: 349-365.
3. Metcalfe DD, (1991) Classification and diagnosis of mastocytosis: current status. J Invest Dermatol 96: 2S-4S.
4. Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, et al. (2007) Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 37: 435-453.
5. Valent P, Akin C, Sperr WR, Horny HP, Metcalfe DD, (2003) Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. Hematol Oncol Clin North Am 17: 1227-1241.
6. Pardanani A, Akin C, Valent P, (2006) Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract Res Clin Haematol 19: 595-615.
7. Hermine O, Lortholary O, Leventhal PS, Catteau A, Soppelsa F, et al. (2008) Case-control cohort study of patients' perceptions of disability in mastocytosis. PLoS ONE 3: e2266.
8. Roskoski R Jr, (2005) Structure and regulation of Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem Biophys Res Commun 338: 1307-1315.
9. Roskoski R Jr, (2005) Signaling by Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem Biophys Res Commun 337: 1-13.
10. Tamborini E, Virdis E, Negri T, Orsenigo M, Brich S, et al. (2010) Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas. Neuro Oncol 12: 776-789.
11. Tests U, (2008) Kit mutations in cancer and their treatment with protein kinase inhibitors. Drugs Fut 33: 161-174.
12. Lennarttson J, Jelacic T, Linnekin D, Shivakrupa R, (2005) Normal and Oncogenic Forms of the Receptor Tyrosine Kinase Kit. Stem Cells Dev 23: 16-43.
13. Letard S, Yang Y, Hanssens K, Palmerini F, Leventhal PS, et al. (2008) Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol Cancer Res 6: 1137-1145.
14. Bodemer C, Hermine O, Palmerini F, Yang Y, Grandpeix-Guyodo C,et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 130: 804-815.
15. Lanternier F, Cohen-Akenine A, Palmerini F, Feger F, Yang Y, et al. (2008) Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS ONE 3: e1906.
16. Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, et al. (2009) Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One 4: e7258.
17. Horny HP, Valent P, (2002) Histopathological and immunohistochemical aspects of mastocytosis. Int Arch Allergy Immunol 127: 115-117.
18. Boncoraglio GB, Brucato A, Carriero MR, Maccagnano E, Robbiolo L, et al. (2005) Systemic mastocytosis: a potential neurologic emergency. Neurology 65: 332-333.
19. Pehlivanidis C, Fotoulaki M, Boucher W, Kempuraj D, Pang X, et al. (2002) Acute stress-induced seizures and loss of consciousness in a ten-year-old boy with cutaneous mastocytosis. J Clin Psychopharmacol 22: 221-224.
20. Schramm A, Grunewald S, Lorenz R, Classen J, Naumann M, (2004) Parkinsonism due to bilateral basal ganglia lesions following mastocytosis-induced hypoxia. J Neurol 251: 1270-1272.
21. Trevisan G, Pauluzzi P, Gatti A, Semeraro A, (2000) Familial mastocytosis associated with neurosensory deafness. J Eur Acad Dermatol Venereol 14: 119-122.
22. Bellamy F, Bader T, Moussy A, Hermine O, (2009) Pharmacokinetics of masitinib in cats. Vet Res Commun 33: 831-837.
23. Hahn KA, Ogilvie G, Rusk T, Devauchelle P, Leblanc A, et al. (2008) Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 22: 1301-1309.
24. Paul C, Sans B, Suarez F, Casassus P, Barete S, et al. (2010) Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol 85: 921-925.
25. Rogers MP, Bloomingdale K, Murawski BJ, Soter NA, Reich P, et al. (1986) Mixed organic brain syndrome as a manifestation of systemic mastocytosis. Psychosom Med 48: 437-447.
26. Laugsand EA, Sprangers MA, Bjordal K, Skorpen F, Kaasa S, et al. (2010) Health care providers underestimate symptom intensities of cancer patients: A multicenter European study. Health Qual Life Outcomes 8: 104.
27. Stiefel R, Die Trill M, Berney A, Olarte JM, Razavi A, (2001) Depression in palliative care: a pragmatic report from the Expert Working Group of the European Association for Palliative Care. Support Care Cancer 9: 477-488.
28. Brintzenhofe-Szoc KM, Levin TT, Li Y, Kissane DW, Zabora JR, (2009) Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type. Psychosomatics 50: 383-391.
29. Sultan S, Hartemann-Heurtier A, Grimaldi A, (2003) [Understanding patients to promote self-regulation in Type 2 diabetes: how to live with an illness beginning before its onset?]. Diabetes Metab 29: S21-30.
30. Temur'iants NA, Shekhotkin AV, Martyniuk VS, (2001) [A role of various components of the diffuse neuroendocrine system in the realization of magnetobiological effects]. Biofizika 46: 901-904.
31. Tadic A, Helmreich I, Mergl R, Hautzinger M, Kohnen R, et al. (2010) Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression. J Affect Disord 120: 86-93.
32. Moller HJ, (2001) Methodological aspects in the assessment of severity of depression by the Hamilton Depression Scale. Eur Arch Psychiatry Clin Neurosci 251 (Suppl 2): II13-20.
33. Lai CH, (2010) Major depressive disorder: gender differences in symptoms, life quality, and sexual function. J Clin Psychopharmacol 31: 39-44.
34. Sultan S, Luminet O, Hartemann A, (2010) Cognitive and anxiety symptoms in screening for clinical depression in diabetes: a systematic examination of diagnostic performances of the HADS and BDI-SF. J Affect Disord 123: 332-336.
35. Martens EJ, Hoen PW, Mittelhaeuser M, de Jonge P, Denollet J, (2010) Symptom dimensions of post-myocardial infarction depression, disease severity and cardiac prognosis. Psychol Med 40: 807-814.
36. Amsterdam JD, Shults J, (2010) Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode. J Clin Psychopharmacol 30: 306-311.
37. Addolorato G, Marsigli L, Capristo E, Caputo F, Dall'Aglio C, et al. (1998) Anxiety and depression: a common feature of health care seeking patients with irritable bowel syndrome and food allergy. Hepatogastroenterology 45: 1559-1564.
38. Bienenstock J, Tomioka M, Matsuda H, Stead RH, Quinonez G, et al. (1987) The role of mast cells in inflammatory processes: evidence for nerve/mast cell interactions. Int Arch Allergy Appl Immunol 82: 238-243.
39. Nautiyal KM, Ribeiro AC, Pfaff DW, Silver R, (2008) Brain mast cells link the immune system to anxiety-like behavior. Proc Natl Acad Sci U S A 105: 18053-18057.
40. Bienenstock J, (2002) Relationships between mast cells and the nervous system. Revue Française d'Allergologie et d'Immunologie Clinique 42: 11-15.
41. Black PH, (2002) Stress and the inflammatory response: a review of neurogenic inflammation. Brain Behav Immun 16: 622-653.
42. Costa-Pinto FA, Basso AS, Russo M, (2007) Role of mast cell degranulation in the neural correlates of the immediate allergic reaction in a murine model of asthma. Brain Behav Immun 21: 783-790.
43. Esposito P, Chandler N, Kandere K, Basu S, Jacobson S, et al. (2002) Corticotropin-releasing hormone and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. J Pharmacol Exp Ther 303: 1061-1066.
44. Esposito P, Gheorghe D, Kandere K, Pang X, Connolly R, et al. (2001) Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. Brain Res 888: 117-127.
45. Theoharides TC, Cochrane DE, (2004) Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol 146: 1-12.
46. Theoharides T, (2009) Autism spectrum disorders and mastocytosis. Int J Immunopathol Pharmaco 22: 859-865.
47. Theoharides TC, (1990) Mast cells: the immune gate to the brain. Life Sci 46: 607-617.
48. Theoharides TC, Spanos C, Pang X, Alferes L, Ligris K, et al. (1995) Stress-induced intracranial mast cell degranulation: a corticotropin-releasing hormone-mediated effect. Endocrinology 136: 5745-5750.
49. Campbell DJ, Kernan JA, (1966) Mast cells in the central nervous system. Nature 210: 756-757.
50. Cirulli F, Pistillo L, de Acetis L, Alleva E, Aloe L, (1998) Increased number of mast cells in the central nervous system of adult male mice following chronic subordination stress. Brain Behav Immun 12: 123-133.
51. Matsumoto I, Inoue Y, Shimada T, Aikawa T, (2001) Brain mast cells act as an immune gate to the hypothalamic-pituitary-adrenal axis in dogs. J Exp Med 194: 71-78.
52. Paus R, Theoharides TC, Arck PC, (2006) Neuroimmunoendocrine circuitry of the 'brain-skin connection'. Trends Immunol 27: 32-39.
53. Bogousslavsky J, Regli F, Delaloye B, Delaloye-Bischof A, Assal G, et al. (1991) Loss of psychic self-activation with bithalamic infarction. Neurobehavioural, CT, MRI and SPECT correlates. Acta Neurol Scand 83: 309-316.
54. Eclancher F, Karli P, (1972) [Combined lesions of ventro-medial hypothalamus and dorso-medial thalamus: effects on interspecific social behavior, emotional reactivity and feeding behavior in the rat]. C R Seances Soc Biol Fil 166: 439-444.
55. Ng WX, Lau IY, Graham S, Sim K, (2009) Neurobiological evidence for thalamic, hippocampal and related glutamatergic abnormalities in bipolar disorder: a review and synthesis. Neurosci Biobehav Rev 33: 336-354.
56. Krack P, Hariz MI, Baunez C, Guridi J, Obeso JA, (2010) Deep brain stimulation: from neurology to psychiatry? Trends Neurosci 33: 474-484.
57. Price JL, Drevets WC, (2010) Neurocircuitry of mood disorders. Neuropsychopharmacology 35: 192-216.
58. Dantzer R, Capuron L, Irwin MR, Miller AH, Ollat H, et al. (2008) Identification and treatment of symptoms associated with inflammation in medically ill patients. Psychoneuroendocrinology 33: 18-29.
59. Dantzer R, Kelley KW, (2007) Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 21: 153-160.
60. Cowen PJ, (2010) Not fade away: the HPA axis and depression. Psychological Medecine 40: 1-4.
61. Valent P HH-P, Escribano L, Longley BJ, Li CY, Schwartz LB, et al.eds. (2001) Mastocytosis (Mast cell disease). World Health Organization (WHO) Classification of tumours Lyon, france IARC Press pp. 291-302.
62. Bech P, Engelhardt N, Evans KR, Gibertini M, Kalali AH, et al. (2005) Why the Hamilton Depression Rating Scale endures. Am J Psychiatry 162: 2396; author reply 2397-2398.
63. Shafer AB, (2006) Meta-analysis of the factor structures of four depression questionnaires: Beck, CES-D, Hamilton, and Zung. J Clin Psychol 62: 123-146.
64. Guelfi JD, Dreyfus JF, Ruschel S, Blanchard C, Pichot P, (1981) [Factorial structure of the Hamilton depression scale. I.]. Ann Med Psychol (Paris) 139: 199-214.
65. Williams JB, (2001) Standardizing the Hamilton Depression Rating Scale: past, present, and future. Eur Arch Psychiatry Clin Neurosci 251 (Suppl 2): II6-12.
66. Reynolds WM, Kobak KA, (1995) Reliability and validity of the Hamilton Depression Inventory: A paper-pendil version of the Hamilton Depression Rating Scale interview. Psychological Assessment 7: 472-483.
67. Bjordal K, Kaasa S, (1992) Psychometric validation of the EORTC Core Quality of Life Questionnaire, 30-item version and a diagnosis-specific module for head and neck cancer patients. Acta Oncol 31: 311-321.